Furthermore, the association between BRAF mutations and HER-2 gene amplification requires further investigation, as well as whether HER-2 monoclonal antibodies may be used to aid EGFR inhibitor resistance in CRC. This evidence concerns the gene BRAF and colorectal carcinoma.